Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo-immunotherapy plus reduced-dose hypofractionated radiotherapy and durvalumab maintenance in unresectable stage III NSCLC
2021-001203-32Phase 2Active
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Sep 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Safety (Grade 3 and Grade 4 possibly related adverse events within 6 months). Started Sep 2021; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-001203-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001203-32.